Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Süleyman Demirel University, Isparta, Turkey.
Department of Pharmacology, Faculty of Pharmacy, Süleyman Demirel University, Isparta, Turkey.
Comb Chem High Throughput Screen. 2020;23(9):877-886. doi: 10.2174/1386207323666200220115154.
Monoamine oxidase and cholinesterase enzymes are very critical enzymes that regulate the level of neurotransmitters such as acetylcholine and monoamines. Monoamine neurotransmitters and acetylcholine play a very important role in many physiological events. An increase or decrease in the amount of these neurotransmitters is observed in a wide range of central nervous system pathologies. Balancing the amount of these neurotransmitters is important in improving the progression of these diseases. Inhibitors of monoamine oxidase and cholinesterase enzymes are important in symptomatic therapy and delaying progression of a group of central nervous system disease manifested with memory loss, cognitive decline and psychiatric disturbances like depression.
In this article, the relationship between central nervous system diseases and the vital role of the enzymes, monoamine oxidase and cholinesterase, is discussed on the pathophysiologic basis, focusing on drug research.
Monoamine oxidase and cholinesterase enzymes are still a good target for the development of novel drug active substances with optimized pharmacokinetic and pharmacodynamic properties, which can maximize the benefits of current therapy modalities.
单胺氧化酶和胆碱酯酶是非常关键的酶,它们可以调节神经递质如乙酰胆碱和单胺的水平。单胺类神经递质和乙酰胆碱在许多生理事件中起着非常重要的作用。在广泛的中枢神经系统疾病中,这些神经递质的数量增加或减少。平衡这些神经递质的数量对于改善这些疾病的进展非常重要。单胺氧化酶和胆碱酯酶抑制剂在症状治疗和延缓以记忆力减退、认知能力下降和抑郁等精神障碍为表现的一组中枢神经系统疾病的进展方面非常重要。
本文在病理生理学基础上,重点讨论药物研究,讨论中枢神经系统疾病与酶,即单胺氧化酶和胆碱酯酶之间的关系。
单胺氧化酶和胆碱酯酶仍然是开发具有优化药代动力学和药效学特性的新型药物活性物质的良好靶点,这可以最大限度地提高现有治疗方式的疗效。